An audit of immunohistochemical marker patterns in meningioma
An audit of immunohistochemical marker patterns in meningioma
复制标题
DOI：
10.1016/j.jocn.2013.06.008
复制
发表时间：
2014-03-01
影响因子：
2
通讯作者：
Mathiesen, Tiit
中科院分区：
文献类型：
--
作者：
Baxter, David S.;Orrego, Abiel;Mathiesen, Tiit
类神经鞘瘤可能表达许多潜在的促生长受体，包括孕酮、生长激素和血管内皮生长因子（VEGF）的受体。这些和其他受体是化疗的潜在靶点。我们已经前瞻性地研究了一组标记物作为常规，以获得标记物的个体表达的数据，这些标记物可以提供抗受体治疗的靶点。对2005年至2008年期间接受脑膜瘤手术的175例连续患者进行了前瞻性分析，包括生长激素受体、胰岛素样生长因子1（IGF-1）、雄激素受体、孕酮受体（PR）抗体和CD 34、VEGF、Ki-67和caspase-3抗体。IGF-1受体（IGF-1 r）、表皮生长因子受体（EGFR）E30和生长激素受体（GHR）的表达在不同组织学分级中是保守的，在88%至94%的脑膜瘤中发现。PR在87%中被检测到，但在侵袭性肿瘤中表达降低。血管标记物如VEGF和CD 34分别在69%和17%的脑膜瘤中检测到。雄激素受体和caspase-3不常见。作为临床常规进行小组分析，以评估其可行性并提供可用于临床环境的数据。三个假定的治疗受体靶点，IGF-1 r，GHR和EGFR E30在绝大多数肿瘤中表达，与PR相反，尽管脑膜瘤的病理分级增加，但PR仍保持表达。我们的数据还表明，抗孕酮治疗和抗血管生成治疗可以针对表达PR或CD 34阳性肿瘤的脑膜瘤患者亚群。(C)2013爱思唯尔有限公司保留所有权利。
Mehingiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routine in order to obtain data of individual expression of markers that may provide targets for anti-receptor treatment. One hundred and seventy-five consecutive patients operated on for meningiomas between 2005 and 2008 were prospectively analysed with antibodies against receptors for growth hormone, insulin-like growth factor 1 (IGF-1), androgen receptors, progesterone receptors (PR) and antibodies against CD34, VEGF, Ki-67 and caspase-3. Expression of IGF-1 receptor (IGF-1r), epidermal growth factor receptor (EGFR) E30 and growth hormone receptor (GHr) was conserved across histological grades and found in 88% to 94% of meningiomas. PR were detected in 87%, but expression decreased in aggressive tumours. Angio-markers such as VEGF and CD34 were detected in 69% and 17% of meningiomas, respectively. Androgen receptors and caspase-3 were uncommon. The analyses of a panel were undertaken as a clinical routine in order to assess its feasibility and to provide data that can be utilised in a clinical setting. Three putative therapeutic receptor targets, IGF-1r, GHr and EGFR E30 were expressed in a large majority of tumours and in contrast to PR maintained expression despite increasing pathological grade of meningioma. Our data also suggest that anti-progesterone therapies and anti-angiogenic therapies could be targeted to subsets of meningioma patients who express PR or have CD34-positive tumours. (C) 2013 Elsevier Ltd. All rights reserved.